Sunshine Lake Pharma Co., Ltd. (HKG:6887)
Hong Kong · Delayed Price · Currency is HKD 37.28
+0.78 (2.14%)
At close: Jun 1, 2026
Sunshine Lake Pharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,815 | 4,019 | 6,295 | 3,745 | 913.79 | |
Revenue Growth (YoY) | 19.81% | -36.15% | 68.08% | 309.83% | -61.08% |
Cost of Revenue | 1,130 | 960.27 | 1,309 | 898.88 | 430.09 |
Gross Profit | 3,685 | 3,059 | 4,986 | 2,846 | 483.7 |
Selling, General & Admin | 2,571 | 1,754 | 1,933 | 1,555 | 880.07 |
Research & Development | 648.69 | 887.65 | 192.29 | 129.61 | 109.67 |
Other Operating Expenses | -153.12 | -68 | 63.83 | 842.69 | -51.11 |
Operating Expenses | 2,994 | 2,700 | 2,196 | 2,523 | 941.81 |
Operating Income | 691.16 | 358.81 | 2,790 | 322.72 | -458.11 |
Interest Expense | -230.2 | -239.79 | -227.4 | -281.65 | -243.81 |
Interest & Investment Income | 38.75 | 62.28 | 62.42 | 6.74 | 11.35 |
Earnings From Equity Investments | 0.05 | 0.29 | -0.03 | - | - |
Currency Exchange Gain (Loss) | 0.1 | 3.3 | -16.86 | -241.43 | 49.2 |
EBT Excluding Unusual Items | 499.85 | 184.9 | 2,608 | -193.62 | -641.37 |
Impairment of Goodwill | - | - | - | -75.9 | - |
Gain (Loss) on Sale of Investments | 10.59 | 6.32 | 4.39 | 522.7 | 19.24 |
Gain (Loss) on Sale of Assets | -3.08 | 18.14 | -0.53 | -0.82 | -19.07 |
Asset Writedown | -67.8 | -68.31 | -485.39 | -212.94 | -25.98 |
Pretax Income | 439.56 | 141.05 | 2,127 | 39.42 | -667.18 |
Income Tax Expense | 169.53 | 116.25 | 270.95 | -9.82 | -79.46 |
Earnings From Continuing Operations | 270.03 | 24.8 | 1,856 | 49.24 | -587.72 |
Minority Interest in Earnings | 2.41 | -232.24 | 136.8 | 27.36 | 0.08 |
Net Income | 272.44 | -207.43 | 1,993 | 76.6 | -587.65 |
Net Income to Common | 272.44 | -207.43 | 1,993 | 76.6 | -587.65 |
Net Income Growth | - | - | 2501.24% | - | - |
Shares Outstanding (Basic) | 488 | 441 | 232 | 232 | 232 |
Shares Outstanding (Diluted) | 498 | 441 | 232 | 232 | 232 |
Shares Change (YoY) | 13.00% | 90.10% | - | - | -20.42% |
EPS (Basic) | 0.56 | -0.47 | 8.59 | 0.33 | -2.53 |
EPS (Diluted) | 0.55 | -0.47 | 8.57 | 0.33 | -2.54 |
EPS Growth | - | - | 2496.14% | - | - |
Free Cash Flow | 319.14 | -561.37 | 1,329 | 1,130 | -1,019 |
Free Cash Flow Per Share | 0.64 | -1.27 | 5.73 | 4.87 | -4.39 |
Gross Margin | 76.54% | 76.11% | 79.21% | 76.00% | 52.93% |
Operating Margin | 14.35% | 8.93% | 44.33% | 8.62% | -50.13% |
Profit Margin | 5.66% | -5.16% | 31.66% | 2.05% | -64.31% |
Free Cash Flow Margin | 6.63% | -13.97% | 21.12% | 30.17% | -111.49% |
EBITDA | 1,099 | 730.96 | 3,172 | 691.48 | -206.55 |
EBITDA Margin | 22.83% | 18.19% | 50.40% | 18.46% | -22.60% |
D&A For EBITDA | 407.99 | 372.15 | 382.3 | 368.76 | 251.55 |
EBIT | 691.16 | 358.81 | 2,790 | 322.72 | -458.11 |
EBIT Margin | 14.35% | 8.93% | 44.33% | 8.62% | -50.13% |
Effective Tax Rate | 38.57% | 82.42% | 12.74% | - | - |